Reich K, Simpson E, Langley R, Warren R, Costanzo A, Saeki H, Almgren P, Gjerum L, Carlsson A, Gooderham M, Pinter A, De Bruin Weller M, Blauvelt A. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. J of Skin [Internet]. 2023 Mar. 13 [cited 2024 Jul. 3];7(2):s143. Available from: https://jofskin.org/33014/index.php/skin/article/view/2027